Javier Garcia

Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T cell activation. Specific control over T cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.

AskBio,  is a fully integrated molecular medicine and technology company with operations around the globe. AskBio remains dedicated to the advancement of transformative gene therapeutics, pioneering research and development, groundbreaking synthetic biology, and scalable cGMP manufacturing. Its robust pipeline includes gene therapy candidates at various clinical stages for neuromuscular, central nervous system, metabolic, and cardiovascular diseases. AskBio also has a portfolio of over 775 molecular and genetic medicine patents and an expansive library of capsids and promoters. Global headquarters are in RTP, NC, and European headquarters in Edinburgh. AskBio’s AAV research centers are in Philadelphia, PA; Columbus, OH; and Paris. Modern clinical, commercial, and synthetic DNA manufacturing facilities are in San Sebastian, Spain. AskBio is a wholly owned, independently operated subsidiary of Bayer. Vision - Pioneering science to create transformative molecular medicines. Mission - Lead innovative science and drive clinical outcomes to transform people's lives. Values: • Be a Pioneer. We are not afraid of the impossible and to innovate to make gene therapies accessible to those in need. • Cultivate Collaboration. Strive to be the best teammate, actively listen, openly communicate, and embrace diverse points of view. • Embrace Responsibility. We are humbled by the enormity of our mission. We hold a relentless commitment to advance science and clinical outcomes for our patients, families, and caregivers. • Raise the Bar. Continuously drive improvements and efficiencies. Seek and provide constructive feedback. Have a bias for learning and action. • Act with Uncompromising Integrity. Be honest, transparent, and committed to doing what’s right in every situation. Make clear commitments and follow through.

En la Fundación Columbus somos conscientes de la importancia que la innovación y las nuevas tecnologías tienen en el ámbito de la salud. En línea con esta visión, asumimos como reto el acercamiento de las nuevas tecnologías a las personas que más lo necesitan, aportando nuestro compromiso y recursos a impulsar iniciativas sociales que ayuden a mejorar su calidad de vida, fundamentalmente en el ámbito de la oncología. Asimismo, trabajamos en promover y divulgar la cultura y la ciencia en España, impulsando en todo el territorio nacional actividades que permitan su acercamiento a la sociedad. Trabajamos en torno a 3 ámbitos: salud, cultura e innovación. Somos una fundación sin ánimo de lucro, inscrita en el Registro de Fundaciones de competencia estatal, con número de registro 1930. Más información en https://www.fundacioncolumbus.org https://www.facebook.com/Fundación-Columbus https://www.instagram.com/fundacioncolumbu

COLUMBUS VENTURE PARTNERS, S.G.E.I.C., S.A es una sociedad gestora de inversión española inscrita en el Registro de Sociedades Gestoras de Entidades de Inversión de tipo Cerrado (SGEIC) de la CNMV con el número 107. Su sede está en calle José Abascal nº 58, 7º Derecha, 28003 Madrid. Nuestro objetivo es que el fondo Columbus Innvierte Life Science, genere altos rendimientos gracias a una cartera selectiva de inversiones en etapa semilla en empresas privadas establecidas dentro del sector sanitario y de ciencias de la vida. Ponemos a su disposición un equipo de inversión sólido, con experiencia a nivel internacional y con una amplia trayectoria en la búsqueda de la excelencia innovadora que proviene de las instituciones académicas españolas. COLUMBUS VENTURE PARTNERS, S.G.E.I.C., S.A proporciona experiencia probada en la creación y la financiación de empresas para acelerar la comercialización y, además, concede a las empresas de su cartera acceso rápido al ecosistema de I+D en el ámbito biotecnológico/farmacéutico de capital de riesgo dinámico del Reino Unido y Boston/Cambridge.

Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T cell activation. Specific control over T cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.